Survey Shows Benefits of Onapgo CSAI in Parkinson's Disease Confidence

A survey from the InfusON trial found continuous subcutaneous apomorphine infusion reduces treatment burden and boosts confidence in daily activities for Parkinson’s patients, with most adapting quickly and recommending it, supporting its recent FDA approval as an effective therapy for motor fluctuations.